Business
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos’ Flagship CARE Oral Medical Devices 5 to 1 Over
About this update from Vivos Therapeutics, Inc.
[{"type":"text","content":"8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos’ Flagship CARE Oral Medical Devices 5 to 1 Over Traditional Oral Appliances\nLITTLETON, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company” (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced positive results from a 7-month, multi-site marketing pilot testing the core assumptions behind Vivos’ new affiliation and medical sleep specialist marketing and distribution model. On June 12, 2024, Vivos announced a new marketing and distribution model under which Vivos is seeking to drive revenue through collaborations with dentists and sleep treatment providers to offer OSA patients a full spectrum of evidence-based treatments for OSA, including Vivos’ advanced, proprietary and FDA-cleared CARE oral medical devices, oral appliances and additional adjunctive therapies and methods. The pilot program results announced today provide evidence of the significant potential of this new model for Vivos. The pilot program was conducted over a 7-month period in seven dental offices and one ear, nose, and throat specialist office located across several states with highly diverse patient demographic profiles. A total of 99 patients were seen during the pilot, which was comprised of 76 adults and 23 children under the age of 12. The results revealed that 79% (60 out of 76) newly diagnosed adult OSA patients chose Vivos’ oral appliance therapy over either continuous positive airway pressure (CPAP) machines or choosing to do nothing, while 5% (4 out of 76) of patients declined all treatment options, and 16% (12 out of 76) patients chose to investigate CPAP as an option before making a final decision. No patients in the pilot program opted for surgical or neurostimulation implant options. A smaller cohort of 23 pediatric patients with orofacial and developmental abnormalities potentially tied to sleep and breathing disorders such as tongue ties, mouth breathing, malocclusion and smaller jaws were also evaluated and treated using Vivos orthodontic guided growth appliances and oral myofun...